Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections

PHASE3CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 4, 2019

Primary Completion Date

October 29, 2020

Study Completion Date

December 14, 2020

Conditions
Urinary Tract Infections
Interventions
DRUG

Temocillin

Intravenous temocillin disodium 2g intravenously/8h Or Renally Adjusted Equivalent (ORAE) in 30-40 min infusion or continuous intravenous (6g/24h) .

DRUG

meropenem or imipenem

Intravenous carbapenem (meropenem 1g intravenously/8h Or Renally Adjusted Equivalent (ORAE) or imipenem 1g intravenously/8h ORAE)

Trial Locations (16)

77

Melun Hospital - CHU Sud, Melun

29000

CHRU La Cavale Blanche, Brest

35000

CHU Pontchaillou, Rennes

75014

APHP - Cochin Hospital, Paris

75015

APHP - Necker-Enfants maladies Hospital, Paris

75018

Bichat hospital, Paris

75020

Groupe Hospitalier Diaconesses Croix Saint Simon, Paris

Tenon Hospital, Paris

Unknown

CHU de Martinique, Fort-de-france

CHU de Grenoble Hospital, Grenoble

APHP - Beaujon Hospital, Paris

APHP - Georges Pompidou European Hospital, Paris

APHP - Saint-Antoine Hospital, Paris

Saint-Joseph Hospital, Paris

CHU de Pau, Pau

CHU de Poitiers, Poitiers

All Listed Sponsors
collaborator

Fondation Hôpital Saint-Joseph

OTHER

collaborator

French National Network of Clinical Research in Infectious Diseases (RENARCI)

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03543436 - Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections | Biotech Hunter | Biotech Hunter